Interface Biologics develops transformative biomedical polymer technologies that enhance the safety and effectiveness of implantable medical devices by reducing thrombosis, inhibiting infection and providing programmable delivery of pharmaceuticals.
Founded in 2001, Interface Biologics Inc. is a spin out from the University of Toronto and the groundbreaking work of Professor Paul Santerre, who continues to be actively involved in the company as Chief Scientific Officer.
IBI has raised over $30M in venture capital financing from the Business Development Bank of Canada (BDC), Covington Venture Partners, the MaRS Investment Accelerator Fund and DSM Venturing.
A major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets.
Funded by the Province of Ontario, the IAF is a seed fund that assists emerging Ontario technology companies to bring their products and services to market. The fund provides a comprehensive platform of resources, people, connections and funding that entrepreneurs and innovators can access to launch their new ventures.